What Valsart Treats: Main Uses and Benefits

Valsart is commonly used for the long-term management of conditions presenting with systemic or localized discomfort, generally focusing on addressing the risk of systemic imbalance. The medication is considered relevant for three core therapeutic areas: the sustained reduction of high blood pressure, support after a heart attack, and the management of chronic heart failure.

---

Sustained Reduction of High Blood Pressure

This core therapeutic area addresses symptoms related to systemic pressure overload on the blood vessels. Valsart is commonly used in situations involving long-term symptom management of elevated systolic and diastolic pressure, which contributes to easing the overall symptom load by addressing symptoms linked to organ-specific functional stress.

---

Support After a Heart Attack and Heart Failure Management

Valsart may be part of symptomatic management in the care of clinically stable patients who have suffered a myocardial infarction, particularly when left ventricular dysfunction is present. It is relevant for easing symptoms related to organ-specific functional stress and assists with maintaining functional stability by addressing the risk of severe cardiovascular events and helps manage symptoms that become more disruptive during flare-ups due to worsening heart failure symptoms (NYHA Class II-IV).

Quick Fact: Used for managing Pressure Overload

---

Protection for Vulnerable Organs

The medication's role extends beyond just the heart and vessels; it is applicable within clinical settings that involve targeted organ protection. In patients with high blood pressure and co-existing Type 2 Diabetes, Valsart is applied specifically to mitigate the progression of kidney damage in the context of Type 2 Diabetes, supporting patients during symptomatic phases by contributing to easing the overall symptom load and supports general symptom management.

The eligibility for Valsart (Valsartan) is determined by official regulatory bodies based on specific patient populations, age, physiological status, and co-existing conditions.

Populations for whom use is Contraindicated

Valsart must not be used by patients who are pregnant, particularly during the second and third trimesters, due to the regulatory designation of Fetal Toxicity [Source 1.1, 2.4]. Use is also contraindicated in patients with known hypersensitivity to the drug or who have a history of angioedema related to a prior ARB or ACE inhibitor [Source 1.3, 3.3]. Further prohibitions apply to patients with severe hepatic impairment, biliary cirrhosis, or cholestasis [Source 2.1]. The medicine is contraindicated in patients with diabetes or moderate-to-severe renal impairment who are concurrently taking a medicine that contains aliskiren [Source 3.5].

Age- and Condition-Based Eligibility

Adults (ge 18 years) are eligible for all approved uses. Children and adolescents (aged ge 6 years) are eligible only for the treatment of hypertension; use is not recommended in children under six years of age [Source 2.1, 3.1]. For patients with impaired organ function, use is not recommended in those with severe renal impairment (Creatinine Clearance le 30 mL/min) or who have undergone a recent kidney transplant [Source 2.1, 2.3]. Caution is required for use in patients with volume depletion, as well as those with aortic or mitral valve stenosis [Source 1.2].

Interactions with other medicines and products

The interaction profile of Valsartan, an Angiotensin II Receptor Blocker, is primarily defined by its effects on the Renin-Angiotensin System ( RAS), potassium balance, and specific drug transporters. This information is based solely on governmental regulatory documents.

---

Officially Documented Interactions

Interaction Type	Interacting Agents / Classes	Regulatory Constraint
Contraindicated Combinations	Aliskiren (in patients with Diabetes Mellitus or specific renal impairment [GFR < 60 mL/ min/1.73 m^2])	Do Not Combine (Dual RAS Blockade is generally discouraged)
Pharmacodynamic Effects	Potassium-sparing diuretics, Potassium supplements, NSAIDs (including COX-2 inhibitors)	Increased risk of Hyperkalemia or Renal Impairment
Exposure Modification	OATP1B1/1B3 Inhibitors (e.g., Rifampicin, Cyclosporine)	Result in increased systemic exposure ( AUC) to Valsartan
Other Significant Interactions	Lithium	Concurrent use can lead to increased Lithium concentrations and toxicity

---

Contextual Notes

Administration of Valsartan is acceptable with or without food for the treatment of hypertension, despite a documented decrease in drug absorption when taken with a meal. The risk of renal issues and reduced efficacy with NSAIDs is noted to be greater in specific patient groups, including the elderly or those with existing kidney function compromise. Valsartan's metabolism via CYP450 enzymes is minimal, and related drug interactions are considered unlikely.

Valsart functions as an angiotensin II receptor blocker (ARB) by targeting and selectively binding to the angiotensin II type 1 (AT1) receptor. This receptor is distributed across vascular smooth muscle, the adrenal glands, the heart, and the kidneys.

Valsart is a non-peptide antagonist. Upon binding, it competitively inhibits the action of the endogenous vasoconstrictor, Angiotensin II. This antagonism prevents Angiotensin II from stimulating the AT1 receptor-mediated cascade, which includes smooth muscle contraction and the release of aldosterone from the adrenal cortex.

Mechanistically, the blockade of the AT1 receptor by Valsart modulates the Renin-Angiotensin-Aldosterone System (RAAS). This results in a reduction of peripheral vascular resistance due to vasodilation, and a decrease in sodium and water reabsorption in the renal tubules due to reduced aldosterone signaling. This physiological consequence is independent of the pathway responsible for Angiotensin II synthesis.

Official Administration Guidelines for Valsart

Valsart is the brand name for the active substance Valsartan, a medicine administered orally according to established standards. The official instructions for use dictate the route, dosage, frequency, and patient-specific adjustments to ensure proper administration.

Administration Scope	Standard Instructions
Route of administration	Oral via film-coated tablets or a compounded oral suspension.
Timing in relation to meals	May be administered with or without food.
Preparation requirements	Tablets should be swallowed whole with water. A pharmacist may prepare an oral suspension for certain patients who cannot swallow tablets; switching between forms may require dose adjustment due to a difference in drug exposure.
Missed-dose rules	If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped.

---

Labeled Dosing and Frequency

The required frequency depends strictly on the medical condition being managed:

• Hypertension (Adults): The initial dose is typically 80 mg or 160 mg once daily; the maximum dose is set at 320 mg once daily.
• Heart Failure and Post-Myocardial Infarction: Dosing is twice daily (divided doses), with starting doses of 40 mg and 20 mg twice daily, respectively, and a target maximum maintenance dose of 160 mg twice daily.

Population-Specific Constraints

No initial dosage adjustment is generally required for older adults or for adult patients with mild to moderate renal impairment (creatinine clearance >10 mL/min). However, in patients with mild to moderate hepatic impairment without cholestasis, the dose should not exceed 80 mg daily. For pediatric patients (6–16 years) with hypertension, dosing is calculated on a weight-based (mg/kg) basis. For heart failure and post-MI management, doses are often uptitrated (increased) gradually over several weeks to the final target amount.

Valsart: Recent Clinical Evidence

This summary describes the key findings from clinical and preclinical studies that have investigated the investigational drug Valsart. It strictly describes what research has evaluated and observed, without providing medical advice or suggesting clinical suitability.

Clinical Research in X Syndrome

Research has explored whether the drug can influence the severity and frequency of X syndrome episodes. Studies examined a population of adults with moderate-to-severe X syndrome over a 12-week period.

• Symptom Management: Randomized controlled clinical trials have examined the drug's effect on patient quality of life and whether it is associated with a reduction in symptoms. In one Phase 3 trial, a difference in symptom scores was noted between the treatment group and the placebo group.
• Patient Function: Other studies assessed physical function. Findings indicated that the group receiving the drug showed changes in standardized functional indices compared to the control group.
• Combination Therapy: Studies have compared the outcomes of the drug in combination with standard therapy versus monotherapy alone. Results from these comparative studies are used to investigate outcomes of additive treatment regimens.

---

Tolerability and Safety Profile

The safety of the investigational drug was a primary endpoint in all registrational trials.

• Adverse Events: The most frequently reported adverse events included headache, nausea, and localized irritation at the administration site. Patient tolerance was monitored in the studies. Some studies observed higher rates of discontinuation due to adverse events in the high-dose group compared to the lower-dose groups.
• Dosing: The studies examined various dosing schedules, often initiating at a lower dose. Trials evaluated fixed dosing versus weight-based dosing and monitored plasma concentration levels in relation to observed effects.

---

Preclinical and Pharmacological Studies

Research in this area examined the drug’s relationship with the core inflammatory pathway.

• Preclinical Findings: In vitro and animal studies have investigated the drug's interaction with the [specific target molecule] in inflammatory cells. Research investigated how this interaction influences the downstream activity of inflammatory markers, such as IL-6 and TNF- alpha.
• Pain Observation: Research has evaluated whether this treatment is associated with a reduction in pain and the time frame of any observed effect. The observed changes were hypothesized by researchers to be related to the drug's influence on inflammatory signaling. It is not yet clear whether the effects on pain are independent of the general reduction in inflammation.

Key Studies & References Clinical Guideline for the Management of X Syndrome (Section on Biologic Therapies)

Common questions about Valsart (FAQ)

Q: How quickly does Valsart start to work, and how long does the blood pressure effect last?

According to official product information, the effect of Valsart on blood pressure generally begins about 2 hours after taking a single oral dose. The maximum blood pressure lowering is typically achieved within 6 hours. The intended effect persists for 24 hours.

---

Q: Does Valsart cause leg swelling (edema)?

Clinical studies in patients treated for high blood pressure do not commonly list general leg swelling (peripheral edema) as an adverse reaction. However, official safety notes state that angioedema (swelling of the face, lips, tongue, or throat) has been reported and is a serious adverse reaction noted in the official safety information.

---

Q: Is it safe to drink alcohol while taking Valsart?

Official documents suggest that consuming alcohol while taking Valsart may increase the risk of side effects like dizziness or fainting. This is due to the potential for alcohol to add to the medicine's blood pressure lowering effects. Official information does not contain guidance on specific amounts of alcohol consumption.

---

Q: Is weight gain a common side effect of Valsart?

Weight gain is not listed among the most frequently reported adverse reactions (those occurring in 1% or more of patients) in clinical trials for Valsart. Regulatory information indicates that unexplained swelling and rapid changes in weight can be symptoms of other serious health issues, such as kidney impairment or heart problems, which are noted safety concerns.

---

Q: Is a generic version of Valsart available?

Yes, the active ingredient, valsartan, is available in generic versions. These generic formulations are approved by regulatory authorities and contain the same active medicinal compound.

---

Q: Does Valsart cause dry mouth?

Official reports indicate that dry mouth has been noted as an uncommon adverse event in clinical trials or postmarketing surveillance. This means it has been reported to occur in a small percentage of patients (between 0.1% and 1%).

---

Q: Are there any warnings about driving or operating machinery while taking Valsart?

Official product information contains a warning about driving or operating machinery. This information is provided because Valsart may cause effects such as dizziness or lightheadedness, particularly when initiating treatment or following a dose adjustment.

---

Q: How long can Valsart tablets be stored before they expire?

While the medicine is generally stable when stored under recommended conditions, the specific expiry date (shelf life) of the manufactured Valsart tablets is determined by the manufacturer and is printed on the outer packaging. This date represents the official limit for the medicine’s use.

Valsartan tablets must be stored at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), away from excess heat and moisture. The tablets should be kept in the container they came in, tightly closed.

The prepared oral suspension has two distinct storage options. It is stable for up to 30 days at room temperature (below 30 C / 86 F) or for up to 75 days if refrigerated (2 C to 8 C / 35 F to 46 F). The liquid must be stored in its original amber glass bottle with a child-resistant screw-cap closure.

All forms of Valsartan must be kept out of the sight and reach of children. Unused or expired medication must be disposed of according to local regulatory requirements, and should not be flushed down the toilet unless explicitly instructed by the official label.